Teva announced it will discontinue a phase 3 trial testing fremanezumab for the treatment of chronic cluster headache.
Following an analysis that showed that the drug was unlikely to meet the study’s main goal, Teva said it will shut down its indication for chronic cluster headaches and only pursue those patients with episodic cluster headaches. This is a fairly large loss for Teva, as the episodic cluster headache market is already crowded.
Teva is up for FDA approval for the prevention of migraine headaches for fremanezumab in September of this year.
Read the press release